Dana Nasim, Nasirian Maryam, Vaseghi Golnaz, Heshmat-Ghahdarijani Kiyan, Ataei Behrooz, Mosayebi Azam, Manteghinejad Amirreza, Javanmard Shaghayegh Haghjooy
Applied Physiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
Infectious Diseases and Tropical Medicine Research Center; and Epidemiology and Biostatistics Department, Health School, Isfahan University of Medical Sciences, Isfahan, Iran.
Eurasian J Med. 2022 Oct;54(3):206-212. doi: 10.5152/eurasianjmed.2022.21088.
There is no conclusive evidence to suggest vitamin D level can prevent or treat infection with the new coronavirus disease 2019. This study aimed to investigate the effects of serum level of vitamin D in patients with coronavirus disease 2019 on death, severity, and hospitalization duration.
Baseline characteristic of patients was extracted from the Isfahan coronavirus disease 2019 registry database (I-CORE). Blood samples were taken from all patients to measure the level of vitamin D (25-hydroxyvitamin D) and categorized. The effect of 25(OH) D on death, severity, and hospitalization duration was analyzed by logistic regression.
Among our study patients, 5.5% had a severe deficiency of vitamin D, 23.7% deficiency, and 24.8% insufficiency. Of the 107 patients who died, 7.5% were severely deficient in vitamin D. We found that vitamin D deficiency had no significant effect on death, disease severity, and hospitalization (P > .05). However, having at least one comorbidity increased the odds of death five times after adjusting age > 60 years and gender (P < .0001). The results showed that among all comorbidities, diabetes has the greatest impact on the outcomes as it raised the odds of death, disease severity, and length of hospital stay by 2.23,1.72, and 1.48, respectively, after controlling the age > 60 and gender (P = .0002, P=.08, P=.012).
The mortality, disease severity, and hospitalization of coronavirus disease 2019 patients seem to be not affected by the low levels of 25(OH)D. However, the synergy between vitamin D levels and comorbidities, age, and gender could affect the outcome of coronavirus disease 2019 patients.
尚无确凿证据表明维生素D水平可预防或治疗2019年新型冠状病毒病感染。本研究旨在调查2019年冠状病毒病患者血清维生素D水平对死亡、严重程度及住院时长的影响。
从伊斯法罕2019年冠状病毒病登记数据库（I-CORE）中提取患者的基线特征。采集所有患者的血样以检测维生素D（25-羟基维生素D）水平并进行分类。采用逻辑回归分析25(OH)D对死亡、严重程度及住院时长的影响。
在我们的研究患者中，5.5%存在维生素D严重缺乏，23.7%缺乏，24.8%不足。在107例死亡患者中，7.5%维生素D严重缺乏。我们发现维生素D缺乏对死亡、疾病严重程度及住院情况无显著影响（P>.05）。然而，在调整年龄>60岁和性别后，至少有一种合并症会使死亡几率增加五倍（P<.0001）。结果显示，在所有合并症中，糖尿病对结局影响最大，在控制年龄>60岁和性别后，它分别使死亡几率、疾病严重程度及住院时长增加2.23、1.72和1.48倍（P=.0002，P=.08，P=.012）。
2019年冠状病毒病患者的死亡率、疾病严重程度及住院情况似乎不受25(OH)D低水平的影响。然而，维生素D水平与合并症、年龄及性别之间的协同作用可能会影响2019年冠状病毒病患者的结局。
